An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.
Video content above is prompted by the following questions:
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More